Johnson & Johnson (NYSE:JNJ) Shares Bought by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 1.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,495 shares of the company’s stock after purchasing an additional 1,463 shares during the period. Snowden Capital Advisors LLC’s holdings in Johnson & Johnson were worth $13,666,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. IFS Advisors LLC raised its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth $32,000. Finally, Conquis Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 2.1%

JNJ stock opened at $149.40 on Friday. The company’s 50-day moving average price is $156.56 and its 200 day moving average price is $154.00. The company has a market cap of $359.47 billion, a P/E ratio of 22.47, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.48%. Johnson & Johnson’s payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on JNJ shares. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, Barclays reduced their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.